The renin-angiotensin system meets the hallmarks of cancer

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 16, Issue 2, 2015, Pages 227-233

  Wegman Ostrosky, Talia ^a,b   Soto Reyes, Ernesto ^a   Vidal Millán, Silvia ^a   Sánchez Corona, José ^b,c  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA DE OCCIDENTE   (Mexico)

Author keywords

angiotensin; angiotensinogen; cancer; hallmarks; Renin angiotensin system

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN INHIBITOR;

ANGIOGENESIS; ANGIONEUROTIC EDEMA; BREAST CANCER CELL LINE; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; COUGHING; DIARRHEA; ENERGY METABOLISM; FAINTNESS; HUMAN; HYPERKALEMIA; HYPOTENSION; INFLAMMATION; KIDNEY FAILURE; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS (TOPIC); METASTASIS; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; CELL MOTION; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR INVASION;

CELL MOVEMENT; ENERGY METABOLISM; HUMANS; INFLAMMATION; NEOPLASM INVASIVENESS; NEOPLASMS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84930921669     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320313496858     Document Type: Review

References (47)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 ; 100: 57-70
2. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011 ; 144: 646-674
3. Vinson GP, Barker S, Puddefoot JR. The renin-angiotensin system in the breast and breast cancer. Endocr Relat Cancer. 2012 ; 19: 1-19
4. Putnam K, Shoemaker R, Yiannikouris F, et al. The renin-angiotensin system: A target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol. 2012 ; 302: 1219-1230
5. Vincent F, Bonnin P, Clemessy M, et al. Angiotensinogen delays angiogenesis and tumour growth of hepatocarcinoma in transgenic mice. Cancer Res. 2009 ; 69: 2853-2860
6. Crowley SD, Coffman TM. Recent advances involving the renin-angiotensin system. Exp Cell Res. 2012 ; 15: 1049-1056
7. Santos RA, Ferreira AJ, Verano-Braga T, et al. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: New players of the renin-angiotensin system. J Endocrinol. 2013 ; 216: 1-17
8. George AJ, Thomas WG, Hannan RD. The renin angiotensin system and cancer: Old dog, new tricks. Nat Rev Cancer. 2010 ; 10: 745-759
9. Dolley-Hitze T, Jouan F, Martin B, et al. Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?. Br J Cancer. 2010 ; 103: 1698-1705
10. Hu F, Morrissey P, Yao J, et al. Development of AT(1) and AT(2) receptors in the ovine fetal brain. Brain Res Dev. 2004 ; 150: 51-61
11. Stoll M, Steckelings UM, Paul M, et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. Br J Cancer. 2010 ; 103: 1698-1705
12. Lewandowska U, Lachowicz-Och'dalska A, Domińska K, et al. Angiotensin II asa factor modulating protein tyrosine kinase activity in two breast cancer lines - MCF-7 and MDA-MB-231. Endokrynol Pol. 2011 ; 62: 151-158
13. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis. 2008 ; 29: 1675-1684
14. Arrieta O, Pineda-Olvera B, Guevara-Salazar P, et al. Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis. Br J Cancer. 2008 ; 8: 160-166
15. Li JM, Mogi M, Tsukuda K, et al. Angiotensin II-induced neural differentiation via angiotensin II type 2 (AT2) receptor-MMS2 cascade involving interaction between AT2 receptor-interacting protein and Src homology 2 domain-containing protein-tyrosine phosphatase 1. Mol Endocrinol. 2007 ; 21: 499-511
16. Li H, Qi Y, Li C, et al. Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells. Mol Cancer Ther. 2009 ; 8: 3255-3265
17. Bouquet C, Lamandé N, Brand M, et al. Suppression of angiogenesis, tumour growth, and metastasis by adenovirus-mediated gene transfer of human angiotensinogen. Mol Ther. 2006 ; 14: 175-182
18. Célérier J, Cruz A, Lamandé N, et al. Angiotensinogen and its cleaved derivatives inhibit angiogenesis. Hypertension. 2002 ; 39: 224-228
19. Fujita M, Hayashi I, Yamashina S, et al. Angiotensin type 1a receptor signalling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumour-associated angiogenesis and tumour growth. Carcinogenesis. 2005 ; 26: 271-279
20. Uemura H, Ishiguro H, Nagashima Y, et al. Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol Cancer Ther. 2005 ; 4: 1699-1709
21. Miyajima A, Kosaka T, Asano T, et al. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumour angiogenesis. Cancer Res. 2002 ; 62: 4176-4179
22. Fujimoto Y, Sasaki T, Tsuchida A, et al. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett. 2001 ; 495: 197-200
23. Imai N, Hashimoto T, Kihara M, et al. Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis. Lab Invest. 2007 ; 87: 189-198
24. Clere N, Corre I, Faure S, et al. Deficiency or blockade of angiotensin II type 2 receptor delays tumourigenesis by inhibiting malignant cell proliferation and angiogenesis. Int J Cancer. 2010 ; 127: 2279-2291
25. Krishnan B, Torti FM, Gallagher PE, et al. Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1. Prostate. 2013 ; 73: 60-70
26. Zhao W, Zhao T, Chen Y, et al. Angiotensin 1-7 promotes cardiac angiogenesis following infarction. Curr Vasc Phrmacol. 2015 ; 13: 37-42
27. Warburg O. On the origin of cancer cells. Science. 1956 ; 123: 309-314
28. Uemura H, Ishiguro H, Ishiguro Y, et al. Angiotensin II induces oxidative stress in prostate cancer. Mol Cancer Res. 2008 ; 6: 250-258
29. Smith GR, Missailidis S. Cancer, inflammation and the AT1 and AT2 receptors. J Inflamm (Lond). 2004 ; 30: 3-7
30. Rodríguez A, Gómez-Ambrosi J, Catalán V, et al. Leptin inhibits the proliferation of vascular smooth muscle cells induced by angiotensin II through nitric oxide-dependent mechanisms. Mediators Inflamm. 2010 ; 2010: 5489-5499
31. Wang L, Hu X, Zhang W, et al. Angiotensin (1-7) ameliorates angiotensin II-induced inflammation by inhibiting LOX-1 expression. Inflamm Res. 2013 ; 62: 219-228
32. Röcken C, Röhl FW, Diebler E, et al. The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer. Cancer Epidemiol Biomarkers Prev. 2007 ; 16: 1206-1212
33. Suganuma T, Ino K, Shibata K, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumour invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res. 2005 ; 11: 2686-2694
34. Krishnan B, Smith TL, Dubey P, et al. Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate. 2013 ; 73: 71-82
35. Keizman D, Huang P, Eisenberger MA, et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. Eur J Cancer. 2011 ; 47: 1955-1961
36. Ishimatsu S, Itakura A, Okada M, et al. Angiotensin II augmented migration and invasion of choriocarcinoma cells involves PI3K activationthrough the AT1 receptor. Placenta. 2005 ; 27: 587-591
37. Carl-McGrath S, Ebert MP, Lendeckel U, et al. Expression of the local angiotensin II system in gastric cancer may facilitate lymphatic invasion and nodal spread. Cancer Biol Ther. 2007 ; 6: 1218-1226
38. Ma TK, Kam KK, Yan BP, et al. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: Current status. Br J Pharmacol. 2010 ; 160: 1273-1292
39. Padhy BM, Gupta YK. Drug repositioning: Re-investigating existing drugs for new therapeutic indications. J Postgrad Med. 2011 ; 57: 153-160
40. Weiss JW, Thorp ML, O'Hare AM. Renin-angiotensin system blockade in older adults with chronic kidney disease: A review of the literature. Curr Opin Nephrol Hypertens. 2010 ; 19: 413-419
41. van der Knaap R, Siemes C, Coebergh JW, et al. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: The Rotterdam Study. Cancer. 2008 ; 15: 748-757
42. Sipahi I, Debanne SM, Rowland DY, et al. Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials. Lancet Oncol. 2010 ; 11: 627-636
43. Wilop S, von Hobe S, Crysandt M, et al. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol. 2009 ; 135: 1429-1435
44. Kim ST, Park KH, Oh SC, et al. How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?. Oncology. 2012 ; 83: 354-360
45. Yuge K, Miyajima A, Tanaka N, et al. Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer. Ann Surg Oncol. 2012 ; 19: 3987-3993
46. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?. Lancet. 1998 ; 352: 179-184
47. Friis S, Sørensen HT, Mellemkjaer L, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: A population-based cohort study in Denmark. J Cancer. 2001 ; 92: 2462-2470